DURHAM, N.C., March 29, 2016 — Recruiting hard-to-find patients and making the most of small data samples are familiar challenges in study of rare cancers, and there’s so much more. How much risk is too much? What about adaptive design and other approaches to easing the burden on patients and shortening development timelines?

Sachin Kulkarni and Juliet Moritz will address these and other aspects of rare oncology research at a webinar on Tuesday, March 29. Rare Oncology Research in the 21st Century will begin at 11 a.m. EDT / 4 p.m. BST / 5 p.m. CEST.

Register today to hear Sachin and Juliet examine positions adopted by authors and research consortia on how to best design and conduct these studies, looking at early indicators such as biomarkers and natural history data. They’ll also review the pending 21st Century Cures Act and its potential impact on oncology research.

Testing new drugs on vulnerable populations requires careful consideration of study design so the fewest possible subjects are exposed to the investigational product, and to ensure that the findings support viable research decisions. Join us for this informative hour.

About Premier Research

Premier Research is a leading contract research organization serving the needs of biotechnology, pharmaceutical and medical device companies worldwide. The company has a wealth of experience in the execution of global, regional, and local clinical development programs with a special focus on addressing unmet needs in such areas as analgesia, CNS, rare diseases, medical device and diagnostics, pediatric and oncology research. Premier Research operates in 84 countries and employs more than 1,000 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. With its mission to improve productivity in clinical development, the company aligns itself with the mission of its customers to bring new medical treatments to patients promptly, accurately, and cost-effectively.